Teva Pharmaceutical Industries Limited (TEVA) Q1 2026 Earnings Call Transcript
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
Overview
The earnings call shows mixed results: a slight revenue increase and improved net income, but declining operating income and free cash flow. The lack of strategic updates and forward-looking risks add uncertainty. The absence of Q&A insights and market cap data further limits sentiment clarity. Overall, a neutral market reaction is expected.
Key Financial Performance
Revenue $3.7 billion, a 2% increase year-over-year, driven by higher sales of generic medicines and biosimilars.
Gross Margin 50.5%, a slight improvement from 50.2% in the prior year, attributed to cost-saving initiatives and favorable product mix.
Operating Income $450 million, a 5% decline year-over-year, due to increased R&D expenses and higher legal costs.
Net Income $300 million, a 10% increase year-over-year, supported by lower tax expenses and improved operational efficiencies.
Free Cash Flow $200 million, a 15% decrease year-over-year, primarily due to higher capital expenditures.
You have reached the limit. Sign up to access full content
Get started
Operating Highlights
The selected topic was not discussed during the call.
You have reached the limit. Sign up to access full content
Get started
Risk or Challenges
Forward-looking statements: The company acknowledges that forward-looking statements involve risks and uncertainties, and there is no guarantee of future performance. This implies potential challenges in achieving projected outcomes or meeting strategic objectives.
You have reached the limit. Sign up to access full content
Get started
Guidance & Outlook
The selected topic was not discussed during the call.
You have reached the limit. Sign up to access full content
Get started
Shareholder Return Plan
The selected topic was not discussed during the call.
You have reached the limit. Sign up to access full content
Get started
Key Q&A
Q:Review of Unclear Management Responses
A:
You have reached the limit. Sign up to access full content
Get started
Earnings Word Cloud
The most frequently occurring keywords in this quarter's earning call
Bank PLC
Barclays Bank
CEO statement
CFO Louise
Chen Scotiabank
Co Research
Competitive Intelligence
Director Eric
Division Ashwani
Division EDT
Division Glen
Division Umer
EDT Jason
Eliyahu Kalif
Emalex transaction
Eric Hughes
Executive VP
Global
Inc Research
Pharmaceutical Industries
President Investor
Relations Competitive
Research Division
Securities
Teva Pharmaceutical
Vice President
material
press release
TEVA Transcript
Teva Pharmaceutical Industries Limited (TEVA) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript
Neutral6-8
Teva Pharmaceutical Industries Limited (TEVA) Presents at Bank of America Global Healthcare Conference 2026 Transcript
Neutral5-12
Teva Pharmaceutical Industries Limited (TEVA) Q1 2026 Earnings Call Transcript
Unknown4-29
The earnings call shows mixed results: a slight revenue increase and improved net income, but declining operating income and free cash flow. The lack of strategic updates and forward-looking risks add uncertainty. The absence of Q&A insights and market cap data further limits sentiment clarity. Overall, a neutral market reaction is expected.
Teva Pharmaceutical Industries Limited (TEVA) Presents at Barclays 28th Annual Global Healthcare Conference Transcript
Neutral3-10
TEVA Report
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
